Cefotaxime (Cefotaxim Navamedic): Uses, Dosage & Side Effects

What Is Cefotaxime and What Is It Used For?

Quick Answer: Cefotaxime is a third-generation cephalosporin antibiotic that kills bacteria by disrupting their cell wall synthesis. It is used to treat serious bacterial infections in the lungs, brain, urinary tract, abdomen, skin, blood, and heart, as well as Lyme disease and gonorrhoea. It is administered only by injection or infusion in a hospital or clinical setting.

Cefotaxime belongs to the cephalosporin class of beta-lactam antibiotics, specifically classified as a third-generation cephalosporin. Like all beta-lactam antibiotics, cefotaxime works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). This disrupts the final stage of peptidoglycan synthesis in the bacterial cell wall, leading to cell lysis and death. The result is bactericidal activity – meaning cefotaxime kills susceptible bacteria rather than merely inhibiting their growth.

Third-generation cephalosporins such as cefotaxime have an expanded spectrum of activity compared to earlier generations, particularly against Gram-negative organisms. Cefotaxime demonstrates excellent activity against many clinically important pathogens including Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, and many Enterobacteriaceae. It also retains useful Gram-positive activity, though it is less active than first-generation cephalosporins against staphylococci.

One of cefotaxime's most important pharmacological properties is its ability to cross the blood-brain barrier, particularly when the meninges are inflamed. This makes it a first-line antibiotic for the empirical treatment of bacterial meningitis, one of the most serious infectious disease emergencies. The World Health Organization (WHO) lists cefotaxime on its Model List of Essential Medicines, reflecting its critical importance in global healthcare.

Approved Indications

Cefotaxim Navamedic is approved for the treatment of severe infections caused by cefotaxime-susceptible bacteria in the following sites:

• Bacterial pneumonia – Infections of the lungs caused by susceptible organisms, including community-acquired pneumonia requiring hospitalisation.
• Complicated urinary tract infections – Including pyelonephritis (kidney infection) and complicated lower urinary tract infections that require parenteral antibiotic therapy.
• Acute bacterial meningitis – Infections of the membranes surrounding the brain and spinal cord. Cefotaxime is a first-line empirical therapy for meningitis caused by S. pneumoniae, N. meningitidis, and H. influenzae.
• Intra-abdominal infections – Including peritonitis, abdominal abscesses, and post-surgical infections. Often combined with metronidazole to cover anaerobic bacteria.
• Skin and soft tissue infections – Serious infections such as cellulitis, wound infections, and infected surgical sites requiring parenteral therapy.
• Genital infections – Including uncomplicated gonorrhoea caused by Neisseria gonorrhoeae, where a single intramuscular dose may be sufficient.
• Endocarditis – Infections of the heart valves, typically as part of combination antibiotic therapy.
• Lyme disease (borreliosis) – Particularly for neuroborreliosis and disseminated Lyme disease requiring parenteral antibiotic treatment. Cefotaxime is recommended as an alternative to ceftriaxone by the Infectious Diseases Society of America (IDSA).
• Bacteraemia (bloodstream infections) – Including sepsis and septicaemia associated with any of the above infections.

In addition, cefotaxime is used for perioperative prophylaxis to prevent surgical site infections. A single dose of 1–2 g is administered as close to the start of the surgical procedure as possible, with an additional dose given if the operation lasts longer than 90 minutes.

What Should You Know Before Taking Cefotaxime?

Quick Answer: Do not use cefotaxime if you are allergic to cephalosporins or have had a severe immediate allergic reaction to penicillin. Tell your doctor about any kidney problems, previous allergies, or gastrointestinal disease before receiving this medicine. Cefotaxime should be used with caution in pregnancy and breastfeeding.

Before receiving cefotaxime, your doctor needs a thorough understanding of your medical history, current medications, and any allergies. This information is essential for ensuring the safe and effective use of this antibiotic. Healthcare professionals administering cefotaxime should have resuscitation equipment readily available, as with all injectable antibiotics, because severe hypersensitivity reactions including anaphylaxis can occur unpredictably.

Contraindications

Cefotaxime must not be used in the following circumstances:

• Allergy to cefotaxime or other cephalosporins – If you have previously experienced an allergic reaction to any cephalosporin antibiotic (e.g. cefuroxime, ceftriaxone, cefalexin), cefotaxime is contraindicated.
• Severe immediate hypersensitivity (Type I reaction) to penicillin – If you have a history of anaphylaxis, angioedema, or immediate severe urticaria following penicillin administration, cefotaxime should not be used due to potential cross-reactivity between beta-lactam antibiotics.
• Previous severe cutaneous reactions to cefotaxime or cephalosporins – If you have ever experienced severe skin peeling, blistering, or mouth sores (such as Stevens-Johnson syndrome or toxic epidermal necrolysis) after taking cefotaxime or other cephalosporins.

When cefotaxime is mixed with lidocaine for intramuscular injection to reduce pain, additional contraindications apply:

• Known allergy to lidocaine or other local anaesthetics of the amide type
• Children younger than 30 months of age
• Heart disease, problems with heart rhythm (heart block), or severe heart failure

Warnings and Precautions

Inform your doctor, pharmacist, or nurse before using cefotaxime if any of the following apply to you:

• Impaired kidney function – Cefotaxime is partially excreted by the kidneys. If you have reduced kidney function, dose adjustments may be necessary, and your blood values may need to be monitored.
• History of penicillin allergy or other allergies – While not all penicillin-allergic patients will react to cephalosporins, there is a small risk of cross-reactivity (estimated at 1–2% for true IgE-mediated penicillin allergy). Your doctor will assess the risk carefully.
• Previous gastrointestinal problems, especially colitis – Antibiotic use can disrupt normal intestinal flora and lead to Clostridioides difficile infection (CDI), a serious form of antibiotic-associated diarrhoea. If you develop diarrhoea containing blood during or after treatment, inform your doctor immediately.
• Treatment lasting more than 10 days – Regular blood counts are required to monitor white blood cell levels (leukocytes). If the white blood cell count decreases significantly (leukopenia), treatment should be discontinued.
• Sodium-restricted diet – Cefotaxim Navamedic contains 2.09 mmol (48 mg) of sodium per gram of cefotaxime, equivalent to 2.4% of the WHO-recommended maximum daily sodium intake of 2 g for adults. This is important for patients on sodium-restricted diets, particularly those receiving high doses.

If you experience loss of consciousness, abnormal movements, or convulsions after receiving this medicine, inform your healthcare team immediately. Neurotoxicity, including seizures, has been reported particularly in patients with renal impairment receiving high doses without appropriate dose adjustment.

Pregnancy and Breastfeeding

There is limited clinical experience with cefotaxime use during pregnancy. Animal studies have not demonstrated teratogenic effects, but the available human data are insufficient to fully evaluate safety. Cefotaxime should only be used during pregnancy when the potential clinical benefit clearly outweighs the potential risk to the foetus. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before receiving this medicine.

Cefotaxime is excreted in breast milk in low concentrations. While the amounts transferred are generally considered small, there is a theoretical risk of affecting the breastfed infant, including sensitisation, disruption of intestinal flora, and diarrhoea. Your doctor will assess whether the benefits of continued breastfeeding outweigh the potential risks. If your infant develops diarrhoea or signs of thrush during your treatment, inform your healthcare provider.

Driving and Operating Machinery

If you experience side effects such as dizziness, drowsiness, seizures, confusion, or abnormal body movements after receiving cefotaxime, you should not drive or operate machinery. These neurological effects are uncommon but can impair your ability to perform tasks requiring concentration and coordination. Most patients receiving cefotaxime are hospitalised, making this less of a practical concern, but outpatient administration (e.g. for Lyme disease) may require this consideration.

How Does Cefotaxime Interact with Other Drugs?

Quick Answer: Cefotaxime has clinically significant interactions with probenecid (which increases cefotaxime levels), aminoglycoside antibiotics (increased nephrotoxicity risk), and loop diuretics such as furosemide (increased nephrotoxicity risk). It must never be mixed in the same syringe or infusion bag with aminoglycosides or sodium bicarbonate solutions.

Drug interactions with cefotaxime can affect either its efficacy or safety. As cefotaxime is administered in a clinical setting, healthcare professionals will manage these interactions, but it is still important for patients to inform their doctors about all medications they are currently taking or have recently taken, including over-the-counter medicines, herbal supplements, and vitamins.

IV Compatibility

From a practical clinical perspective, cefotaxime is compatible with the following intravenous solutions: 0.9% sodium chloride, 5% glucose, 10% glucose, sodium lactate, and Ringer-lactate solution. It is also compatible with metronidazole infusion (500 mg/100 mL), gelatine solutions (Haemaccel), and dextran solutions. However, it must never be mixed in the same syringe or infusion container with aminoglycosides or sodium bicarbonate solutions due to chemical incompatibility that can lead to inactivation of one or both drugs.

What Is the Correct Dosage of Cefotaxime?

Quick Answer: The standard adult dose of cefotaxime is 2–6 g per day in divided doses (every 6–8 hours), given by IV injection, IV infusion, or IM injection. For life-threatening infections, doses up to 12 g/day may be used. Children typically receive 100–150 mg/kg/day in divided doses. Dose reduction is required in patients with significant kidney impairment.

Cefotaxime is always administered by healthcare professionals in a clinical setting. Your doctor will determine the appropriate dose based on the severity and type of infection, the causative organism (if identified), and your overall health status including kidney function. The powder must be reconstituted with sterile water for injection before administration.

Adults

For adults and adolescents over 12 years of age, the standard daily dose of cefotaxime ranges from 2 g to 6 g, administered in equally divided doses at 6–8 hour intervals. The exact dose depends on the severity and type of infection. For most moderate infections, 1 g administered every 8 hours (3 g/day) is a common starting regimen. For severe infections caused by unidentified organisms, infections of unknown origin, or life-threatening infections, the total daily dose can be increased up to 12 g, divided into doses given at 6–8 hour intervals.

For infections caused by susceptible strains of Pseudomonas species, daily doses exceeding 6 g are typically required due to the higher minimum inhibitory concentrations (MICs) for these organisms. Treatment of uncomplicated gonorrhoea requires only a single intramuscular or intravenous dose of 0.5–1 g.

Children

The recommended dose range for children aged 1 month to 12 years is 100–150 mg/kg/day, divided into 2 to 4 doses (given at 6–12 hour intervals). For life-threatening infections, including bacterial meningitis, doses up to 200 mg/kg/day may be administered. Weight-based dosing ensures that children receive appropriate therapeutic concentrations while minimising the risk of toxicity.

For neonates (0–28 days old), the recommended dose is 50 mg/kg/day divided into 2–4 doses. In severe neonatal infections, doses of 150–200 mg/kg/day have been used successfully. An important clinical advantage of cefotaxime in neonates is that, unlike ceftriaxone, it does not displace bilirubin from albumin binding sites, eliminating the risk of kernicterus (bilirubin encephalopathy). This makes cefotaxime the preferred third-generation cephalosporin for neonatal infections.

Perioperative Prophylaxis

For the prevention of surgical site infections, a single dose of 1–2 g is administered as close to the start of the surgical procedure as possible. If the operation lasts longer than 90 minutes, an additional prophylactic dose may be given. The goal of perioperative prophylaxis is to achieve adequate tissue concentrations of the antibiotic at the time of potential bacterial contamination.

Overdose

Since cefotaxime is administered by healthcare professionals in a clinical setting, overdose is unlikely. However, if excessive doses are given, symptoms may include neurological toxicity (seizures, encephalopathy, confusion) particularly in patients with impaired renal function. There is no specific antidote for cefotaxime overdose. Management is supportive, and cefotaxime can be removed from the body by haemodialysis. If you have any concerns about the amount of medication you have received, speak with your healthcare team.

What Are the Side Effects of Cefotaxime?

Quick Answer: The most common side effect is pain at the injection site (affecting >1 in 10 patients). Uncommon side effects include changes in blood cell counts, elevated liver enzymes, skin rash, and diarrhoea. Rare but serious side effects include severe allergic reactions (anaphylaxis), Stevens-Johnson syndrome, C. difficile colitis, and seizures. Seek immediate medical attention for any signs of a severe allergic reaction.

Like all medicines, cefotaxime can cause side effects, although not everybody gets them. The frequency of side effects is classified according to international convention based on how commonly they occur during clinical use and post-marketing surveillance. Understanding the potential side effects helps patients and caregivers recognise when to seek medical attention and provides a basis for informed discussion with healthcare providers.

Antibiotic-Associated Diarrhoea

Antibiotic therapy, including cefotaxime, can disrupt the normal bacterial flora of the gastrointestinal tract and predispose patients to overgrowth of Clostridioides difficile, a toxin-producing bacterium. C. difficile infection ranges from mild diarrhoea to life-threatening pseudomembranous colitis. Symptoms typically include watery diarrhoea (which may contain blood or mucus), abdominal cramps, and fever. If you develop persistent or severe diarrhoea during or within several weeks after completing cefotaxime treatment, you should inform your doctor immediately. Do not take any anti-diarrhoeal medicines without consulting your healthcare provider, as some can worsen the condition.

Superinfection

As with all broad-spectrum antibiotics, prolonged use of cefotaxime may lead to overgrowth of non-susceptible organisms, including fungi (such as Candida). This is particularly a concern during extended treatment courses. Your healthcare team will monitor for signs of secondary infection and take appropriate action if needed, which may include antifungal therapy or a change of antibiotic.

How Should You Store Cefotaxime?

Quick Answer: Store unopened vials below 25°C, protected from light, in the original packaging. Reconstituted solutions should be used immediately. If not used immediately, they may be stored for up to 12 hours at room temperature or 24 hours refrigerated (2–8°C) under validated aseptic conditions. Do not use after the expiry date.

Proper storage of cefotaxime is essential to maintain the chemical stability and sterility of the product. Since cefotaxime is a hospital-use medication, storage is typically managed by pharmacy and nursing staff, but understanding storage requirements is important for all healthcare settings where the drug may be used.

Unopened vials of Cefotaxim Navamedic should be stored at temperatures not exceeding 25°C and must be kept in the original packaging to protect from light. Cefotaxime is a light-sensitive compound, and exposure to light can accelerate degradation and discolouration of the powder.

Reconstituted Solutions

From a microbiological standpoint, reconstituted solutions of cefotaxime should ideally be used immediately after preparation. If the reconstituted product is not used immediately, the following storage guidelines apply (provided preparation was carried out under controlled and validated aseptic conditions):

• Room temperature (up to 25°C): Maximum 12 hours
• Refrigerated (2–8°C): Maximum 24 hours
• Mixed with non-standard infusion solutions: Maximum 6 hours at room temperature

Compatible standard infusion solutions include 0.9% sodium chloride, 5% glucose, 10% glucose, sodium lactate, and Ringer-lactate. When mixed with other infusion solutions such as electrolyte solutions, gelatine solutions, or dextran solutions, the stability period is reduced to 6 hours at room temperature.

Reconstituted solutions normally have a pale yellow colour. If the solution appears bright yellow, brownish, or contains visible particles, it should not be used and must be discarded. Any unused medicine should be disposed of in accordance with local pharmaceutical waste regulations – never through household waste or down the drain.

What Does Cefotaxime Contain?

Quick Answer: Each vial contains cefotaxime sodium as the sole active ingredient (equivalent to 1 g of cefotaxime). There are no other excipients. The product is a white to slightly yellow powder supplied in glass vials.

Cefotaxim Navamedic has a remarkably simple formulation. The sole active substance is cefotaxime sodium, which is the sodium salt form of cefotaxime. This sodium salt form provides the water solubility needed for reconstitution and injectable administration. Notably, there are no additional excipients, fillers, buffers, or preservatives in the product – each vial contains only the pure active pharmaceutical ingredient.

The product is supplied as a white to slightly yellow powder in Type I glass vials, sealed with a rubber stopper and an aluminium cap with a plastic flip-off disc. The glass vials are available containing 0.5 g, 1 g, or 2 g of powder, packaged in boxes of 10 vials. The 1 g strength is the most commonly prescribed formulation.

Sodium Content

Each gram of cefotaxime in Cefotaxim Navamedic contains approximately 2.09 mmol (48 mg) of sodium. This corresponds to 2.4% of the WHO-recommended maximum daily sodium intake for adults. While this is a relatively modest amount per gram, it becomes clinically relevant for patients receiving high daily doses (e.g. 12 g/day would contribute approximately 576 mg of sodium) or for patients on strict sodium-restricted diets, such as those with heart failure, severe hypertension, or chronic kidney disease. Healthcare providers should factor in this sodium load when calculating total daily sodium intake for these patients.

How Is Cefotaxime Prepared and Administered?

Quick Answer: Cefotaxime is prepared by dissolving the powder in sterile water for injection and is given by slow IV injection (3–5 minutes), IV infusion (20–60 minutes), or deep IM injection. It should only be prepared and administered by trained healthcare professionals. Rapid IV injection through a central venous catheter has been associated with potentially life-threatening arrhythmias.

Cefotaxime is a hospital-use medication that requires professional preparation and administration. The following information is primarily for healthcare professionals, but understanding how your medicine is given can help you feel more informed and ask relevant questions about your treatment.

Intravenous Injection

For direct IV injection, 1 g of cefotaxime is dissolved in at least 4 mL of sterile water for injection (0.5 g in 2 mL, 2 g in 10 mL). The vial is shaken until all powder is completely dissolved. The entire contents are then drawn up into a syringe and injected slowly over 3–5 minutes. It is critically important that IV injection is administered slowly, as post-marketing surveillance has identified cases of potentially life-threatening cardiac arrhythmias in a very small number of patients who received rapid IV administration through a central venous catheter.

Intravenous Infusion

For IV infusion, 1–2 g of cefotaxime is dissolved in 40–100 mL of sterile water for injection, or alternatively in compatible infusion solutions such as 0.9% sodium chloride, 5% glucose, 10% glucose, sodium lactate, or Ringer-lactate solution. The infusion is administered over 20–60 minutes. This method of administration is generally preferred for higher doses and reduces the risk of local irritation at the injection site.

Intramuscular Injection

For IM injection, the powder is reconstituted with sterile water for injection using the same volumes as for IV injection. To reduce injection site pain, a solution of 0.5–1% lidocaine hydrochloride may be used as the diluent instead of sterile water (adults only – never in children under 30 months). The solution must be administered as a deep intramuscular injection, typically into the gluteus maximus or lateral thigh. Solutions prepared with lidocaine must never be administered intravenously.